Spleens

1,2-Dioleoyl-sn-glycero-3-phosphate sodium salt (18:1 PA sodium salt) is an anionic lipid that can be used to prepare liposomes, micelles and artificial membranes.

5A2-SC8 is an ionizable amino lipid in lipid nanoparticles (LNPs) that shows high delivery potential and low in vivo toxicity, enabling efficient delivery of small RNAs such as siRNA and miRNA into tumor cells. 5A2-SC8 LNPs can confer a unique delivery fate of RNA within the liver, thereby changing the therapeutic outcomes in cancer models.

PPZ-A10 is an ionizable cationic lipid. PPZ-A10 preferentially delivers mRNA to liver and spleen immune cells. Pi-LNPs containing PPZ-A10 can effectively deliver mRNA/siRNA to solid tumors.

TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency.

93-O17S is an ionizable lipid. 93-O17S is involved in the construction of LNP. 93-O17S can achieve mRNA delivery to the spleen.

DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.

DSPE-PEG3400-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG3400-VIP can be used for drug delivery.

DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery.

DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.

A28-C6B2 is an ionizable cationic lipid with a pK_a of 6.43, and can be used to generate lipid nanoparticles (LNPs) for mRNA delivery in vivo. A28-C6B2 can be studied in research for enhancing the selective delivery of mRNA to the spleen, particularly to antigen-presenting cells.

CP-LC-1422 is a homocysteine-derived ionizable amino lipid with high RNA delivery capability and can mediate high-level protein expression in vivo. CP-LC-1422 exhibits significant spleen targeting via intravenous injection in a lipid nanoparticle (LNP) formulation with no significant toxicity observed.

Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3⁺CD8⁺ central and CD3⁺CD8⁺ effector memory T cells and decrease the percentage of CD3⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model.

Lipid 119-23 is an ionizable cationic lipid which can be utilized in the formation of lipid nanoparticles and the delivery of mRNA. Lipid 119-23 exhibits an enhanced capability to express functional mCre in several categories of immune cells, spanning the liver, spleen and lung.

a12k4E-Ca is a C-terminal glutamate-modified peptidogenic ionizable lipid that can be used for the preparation of lipid nanoparticles (LNPs). a12k4E-Ca preferentially accumulates in the spleen in vivo, acts as a carrier to mediate spleen-selective mRNA delivery, and enables spleen-specific Cre recombinase-mediated gene editing. a12k4E-Ca restores serum biochemical parameters and cytokines/chemokines. a12k4E-Ca can be used in studies related to LNP preparation.